FindTrial
Sign In

Siplizumab

DRUG8 trials

Sponsors

Nefro Avillion Clinical Development LLC, National Cancer Institute (NCI), National Institute of Allergy and Infectious Diseases (NIAID), Massachusetts General Hospital, Columbia University

Conditions

Anemia, Sickle CellAutoimmune HepatitisAutoimmune Liver DiseaseChimeraCirrhosis, LiverEnd Stage Liver DIseaseGamma Delta Hepatosplenic T-Cell LymphomaHidradenitis Suppurativa

Early Phase 1

Evaluate the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa.
RecruitingNCT06326476
University of Alabama at BirminghamHidradenitis Suppurativa
Start: 2025-05-09End: 2028-07-31Target: 12Updated: 2026-09-01

Phase 1

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas
CompletedNCT01445535
National Cancer Institute (NCI)T-Cell Peripheral Lymphoma, Gamma Delta Hepatosplenic T-Cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma +1
Start: 2009-01-13End: 2020-10-22Updated: 2021-11-03
Siplizumab in T1DM
TerminatedNCT05574335
National Institute of Allergy and Infectious Diseases (NIAID)Type 1 Diabetes Mellitus
Start: 2023-05-18End: 2025-10-20Updated: 2026-07-28
Delayed Tolerance Through Mixed Chimerism
Active, not recruitingNCT05900401
Massachusetts General HospitalKidney Failure, Kidney Transplant; Complications, Chimera
Start: 2023-10-01End: 2030-12-31Target: 20Updated: 2025-12-09
Siplizumab for Sickle Cell Disease Transplant
TerminatedNCT06078696
Columbia UniversityAnemia, Sickle Cell
Start: 2023-09-28End: 2025-12-11Updated: 2026-06-10
A Study of SIPLIZUMAB in AILD and LT Patients
RecruitingNCT06455280
Elizabeth C. VernaAutoimmune Liver Disease, Liver Transplant Disorder, Autoimmune Hepatitis +3
Start: 2024-09-11End: 2028-03-31Target: 8Updated: 2025-11-24

Phase 2

A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplant
RecruitingNCT07508787
Nefro Avillion Clinical Development, LLCRenal Transplant Failure and Rejection
Start: 2026-06-29End: 2028-03-28Target: 120Updated: 2026-09-02
A Phase 2b, Randomized, Multicenter, Double-Blind, Dose-Finding, Active-Controlled Study of Siplizumab (TCD601) Compared to Rabbit Anti-Thymocyte Globulin in Renal Transplant Recipients Requiring Induction Therapy and Receiving Standard of Care Immunosuppression with Tacrolimus, Mycophenolic Acid and Corticosteroids (MODERNIZE 1)
Not yet recruitingCTIS2026-525646-29-00
Nefro Avillion Clinical Development LLCRenal Transplantation
Target: 8Updated: 2026-08-26